Clobutinol

Clobutinol
Clinical data
Trade names	Biotussin, Lomisat, Pertoxil, Silomat
AHFS/Drugs.com	International Drug Names
Routes of; administration	oral
ATC code	R05DB03 (WHO) ;
Legal status
Legal status	Withdrawn; (EU)
Identifiers
	IUPAC name (RS)-1-(4-chlorophenyl)-4-dimethylamino-2,3-dimethyl-butan-2-ol;
CAS Number	14860-49-2 ;
PubChem CID	26937;
DrugBank	DB09004 ;
ChemSpider	25085 ;
UNII	1NY2IX043A;
KEGG	D07716 ;
ChEMBL	ChEMBL1474889 ;
CompTox Dashboard (EPA)	DTXSID2022838 ;
ECHA InfoCard	100.035.373
Chemical and physical data
Formula	C14H22ClNO
Molar mass	255.79 g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES Clc1ccc(cc1)CC(O)(C)C(C)CN(C)C;
	InChI InChI=1S/C14H22ClNO/c1-11(10-16(3)4)14(2,17)9-12-5-7-13(15)8-6-12/h5-8,11,17H,9-10H2,1-4H3 ; Key:KVHHQGIIZCJATJ-UHFFFAOYSA-N ;
	(what is this?) (verify)

Clobutinol is a cough suppressant formerly distributed by Boehringer Ingelheim and its licensees under the names Lomisat and Silomat, by Bioter as Biotussin, and by Violani-Farmavigor as Pertoxil. It has been withdrawn from the market worldwide.

Side effects and withdrawal

Side effects include drowsiness, dizziness, insomnia, nausea, vomiting, and abdominal discomfort.^[1] Studies in 2004 had indicated that clobutinol has the potential to prolong the QT interval.^[2] Clobutinol was in 2007 determined to cause cardiac arrhythmia in some patients.^[3]

Boehringer Ingelheim products containing clobutinol were voluntarily withdrawn from sale in Germany, and the rest of the world, on August 31, 2007.^[4]

The approval for Germany and the EU was revoked in 2008.^[5]

Prior to withdrawal, it was available throughout Europe and Central America, as well as in South Africa. Trade names include Biotussin, Lomisat (Spain), Pertoxil (Italy), and in most of the world, Silomat.^[6]

References

^ Schlesser JL (1991). Drugs Available Abroad, 1st Edition. Derwent Publications Ltd. p. 29. ISBN 0-8103-7177-4.
^ Bellocq C, Wilders R, Schott JJ, Louérat-Oriou B, Boisseau P, Le Marec H, et al. (November 2004). "A common antitussive drug, clobutinol, precipitates the long QT syndrome 2". Molecular Pharmacology. 66 (5): 1093–102. doi:10.1124/mol.104.001065. PMID 15280442. S2CID 12883606.
^ "Clobutinol-haltige Arzneimittel: BfArM ordnet Widerruf der Zulassung an". BfArM (German Federal Institute for Drugs and Medical Devices). 2007-08-31. Archived from the original on 2012-04-01. Clobutinol: BfArM orders cancellation of approval
^ "Boehringer Ingelheim voluntarily withdraws its clobutinol containing medications". Boehringer Ingelheim. 2007-08-31. Archived from the original on 2012-01-27.
^ "Cancellation of approval" (PDF). BfArM (German Federal Institute for Drugs and Medical Devices). 2008-06-06. Archived from the original (pdf) on 2012-04-01. Die Zulassungen für die o.g. Arzneimittel werden mit sofortiger Wirkung widerrufen.
^ Schlesser JL (1991). Drugs Available Abroad, 1st Edition. Derwent Publications Ltd. p. 29. ISBN 0-8103-7177-4.

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.

[1] Schlesser JL (1991). Drugs Available Abroad, 1st Edition. Derwent Publications Ltd. p. 29. ISBN 0-8103-7177-4.

[pmid15280442-2] Bellocq C, Wilders R, Schott JJ, Louérat-Oriou B, Boisseau P, Le Marec H, et al. (November 2004). "A common antitussive drug, clobutinol, precipitates the long QT syndrome 2". Molecular Pharmacology. 66 (5): 1093–102. doi:10.1124/mol.104.001065. PMID 15280442. S2CID 12883606.

[3] "Clobutinol-haltige Arzneimittel: BfArM ordnet Widerruf der Zulassung an". BfArM (German Federal Institute for Drugs and Medical Devices). 2007-08-31. Archived from the original on 2012-04-01. Clobutinol: BfArM orders cancellation of approval

[4] "Boehringer Ingelheim voluntarily withdraws its clobutinol containing medications". Boehringer Ingelheim. 2007-08-31. Archived from the original on 2012-01-27.

[5] "Cancellation of approval" (PDF). BfArM (German Federal Institute for Drugs and Medical Devices). 2008-06-06. Archived from the original (pdf) on 2012-04-01. Die Zulassungen für die o.g. Arzneimittel werden mit sofortiger Wirkung widerrufen.

[6] Schlesser JL (1991). Drugs Available Abroad, 1st Edition. Derwent Publications Ltd. p. 29. ISBN 0-8103-7177-4.

[1]

[2]

[3]

[4]

[5]

[6]

Side effects and withdrawal

See also

References